Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Boan Bio Approved to Start Trials of Bispecific Antibody for CEA Solid Tumor Cancers

publication date: May 19, 2023

Boan Biotech, a Shandong biologics company spun out of Luye Pharma, was approved to start China trials of BA1202, a CEACAM5 (CEA)/CD3 bispecific antibody. The candidate is aimed at CEA-positive solid tumors including colorectal cancer, non-small cell lung cancer, pancreatic cancer and gastric cancer. BA1202 is the first CEA/CD3 bispecific antibody approved for a clinical trial in China. Boan is a biotech company that completed an IPO in Hong Kong in late 2022. The company, which focuses on novel biologics and biosimilars, had been the Luye Pharma’s biologic drug subsidiary. More details....

Stock Symbol: (HK: 6955)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital